Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
JPM bought around 22m shares.
How's that compare to the CEO's free over 7m options?
His options must be considered huge if 22m shares bought by an institution buying 22m shares is.
That's my point, no evidence of significant buying nor holding 2021, 2022, 2023 by institutionS.
The CEO gets awarded over 7m options < year ago, exercisable in a year and then there's interest.
It's been talked up.
TLY have around 50 vacancies with around 1/2 advertised recently in January. The oldest vacancy is only about 5 weeks old, so older ones have been filled.
If they had cash problems then they wouldn't currently have c50 vacancies, would they?
https://eur232.dayforcehcm.com/CandidatePortal/en-GB/totallygroup
Magoo247
Read my posting history.
The same happened at rthm, trmr, byot, tap etc etc
Rampers were saying similar whilst I posted the bear points/red flags. Each one of them crashed 80-90% due to the red flags I posted.
Read about trmr from around page 50.
https://www.lse.co.uk/profiles/stt1/
If you believe HVO has no bear points/red flags then feel free to load up and continue to hold.
I see problems/red flags with:
the business model,
lack of strong revenue growth,
sp already close to company brokers targets,
huge options for CEO,
£31m total liabilities
No evidence of significant buying (TR1s) and holding by institutions > 3%.
Huge shares on loan, 10-11m during of 2023.
The fact the CFO left immediately and there was no TU tells me she resigned and was not pushed. I doubt any company would prepare and issue a TU immediately upon receiving a CFO's resignation.
If they were planning to sack the CFO then they would have planned a replacement.
So I think she resigned and being a CFO, left immediately.
Companies have other team members who are able to work whilst staff are away. After all, the company wouldn't have stopped working if the CFO had gone on a year's maternity leave or a long holiday.
The question is why she resigned? I doubt we will ever know due to confidentiality clauses.
JimmyCdee
" I could however be reading things wrong, anyone got any thoughts?"
The shares are trading close to the company's own Nomad target. The previous NOMAD, who was replaced recently had a 29p target based on the takeover price of, what they considered was a UK Peer.
Therefore, I think a lot of investors will see this as potential is already factored in.
I believe the company is being talked up as the CEO has huge 7m options, which were awarded a year ago.
My bear points/red flags:
£200m mcap for a company with £56m revenues, not profit, revenues!!
CEO has huge 7m options
questionable business model
No evidence of significant buying nor holdings by InstitutionS in 2021, 2022, 2023.... If there was strong growth then Institutions would be scrambling to buy.
No evidence of significant revenue growth, so I believe business has matured.
Huge liabilities of £31m as of latest AR - fy2022.
Kingy,
"Hi Silky ..as you perceive Mo's options to be a red flag rather than a normal long term incentive plan"
Whenever there's huge options awarded to 1 director then I see it as a red flag.
A similar happened at RTHM, which I also saw as a red flag. The shares crashed 80%.
The huge options together with the holdings by CEO and CF says to me that this is being talked up.
Look at the options awarded to the CEO, less than a year ago, exercisable in a year and the conditions attached.
These and the number of shares bought by him, tells you why the company is being talked up.
"The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the date Mr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company.
Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance.
https://polaris.brighterir.com/public/hvivo/news/rns/story/x21q5mw/export
CEO also bought 500k shares at 9.8p 1.5 yrs ago.
https://polaris.brighterir.com/public/hvivo/news/rns/story/w13k73r
Plus add to the CEO options and purchase 1.5yrs ago, CF also bought over 1m shares at 26.5p 2.5years ago.
The current sp of 28p means CF is now finally back in profit on those buys.
https://polaris.brighterir.com/public/hvivo/news/rns/story/w13k89r
There's also lots of PIs on here who were also holding at higher prices, 40p++, and so need the sp to move higher so they can sell.
Moniman,
There's no need for personal abuse if someone posts an opinion which doesn't suit you.
When posters resort to personal abuse, they have lost the argument.
I'm posted my opinions based on facts which are in the public domain.
If you disagree then counter the bear points, load up and hold.
Look at the HVO posters posting on TLY thread, Moniman, BillB, TheSoundMan, Shandy
https://www.lse.co.uk/ShareChat.html?ShareTicker=TLY&share=Totally
https://www.lse.co.uk/profiles/moniman/
Moniman,
"£1 target from MF is not unrealistic looking at the projections."
So, obviously you are backing your assertion, are loading up big time at 28p+++ and won't sell a single share until they reach £1.
After all, according to you, the £1 is realistic.
Kilman,
Dividend.
Last year was a 'special dividend'.
This year they intend to pay a 'nominal dividend'.
I'd expect a nominal dividend to be lower than the special. We'll know soon enough.
From fy2022 results:
One-off special dividend of c.£3.0m, being 0.45p per share reflecting strong cash generation during the year, payable on 9 June 2023 to shareholders on the register on 5 May 2023."
https://polaris.brighterir.com/public/hvivo/news/rns/story/rnk452r/export
From H1:
Dividend
"The Company intends to pay a nominal annual dividend going forward, details of which will be announced alongside publication of the Group's audited results for FY23."
https://polaris.brighterir.com/public/hvivo/news/rns/story/rgz9g3w/export
Nearly 400 trades already!
Looks like some PIs churning trades to me.
odd small trades, followed by larger sells..
eg look at trades at 11.39...
2 small buy trades 101 & 165, £30 & £50
then a couple of minutes later 2x50k sells.
StrictlyZinc,
"Rare insight from them for a change??"
Motley have mentioned HVO several times over the past year or so. Not a rare insight from them at all.
7th Dec 2022 https://www.fool.co.uk/2022/12/07/1-penny-stock-under-13p-id-snap-up-right-now/
7th Jan 2023 https://www.fool.co.uk/2023/01/07/1-penny-stock-im-buying-right-now/
12th Feb 2023 https://www.fool.co.uk/2023/02/12/this-ex-penny-stock-is-up-111-in-6-weeks-should-i-buy-more/
29th July 2023 https://www.fool.co.uk/2023/07/29/this-ex-penny-stock-just-paid-its-first-ever-dividend-heres-how-much/
Jimcdee,
"I am surprised we don't have more of a rise in SP."
There wasn't anything new in the presentation.
Look at the hundreds of small trades to push the sp higher.
There's a lot of churning going on.
This is being talked up.
C40% held by multiple institutions.
Plus some have been increasing since H1 end.
Evidence:
c40% held by multiple institutions
https://www.totallyplc.com/investors/shareholder-information/shareholdings/
Holdings increased:
https://ir.design-portfolio.co.uk/viewer/100/60322
https://ir.design-portfolio.co.uk/viewer/100/60993
Moniman
"New contracts secured in the period contributing £14.8 million of annualised revenue."
£14.8m NEW contracts, announced at H1.
Plus the recently announced £13m, which was 30% uplift on the original.
Mcap only £8.5m
They stated they have £37m cash.
Compare that to the latest published AR, for fy2022, they have total liabilities of £31m.
Cash increase due to recent non-refundable booking fees. Cash will decline as they have regular monthly outgoings as well as project costs. If they had so much cash then why didn't they pay for the new facility themselves instead of clients? Those clients would then be given favourable terms, which could be detrimental for new or other clients.
Trout,
As per my previous post, where's the TR1s? Where's the significant holdings >3% by institutionS?
My previous post:
"There's no evidence of significant buying by institutionS in 2021, 2022, 2023. Where's the TR1s?"
"No evidence of significant holdings > 3% by institutionS."
"Institutions have been buying in for the last 8 months because the story is positive"
Since the CEO was awarded the huge options < a year ago and exercisable in a year. Coincidence?
hundreds of small trades today. Yet there aren't hundreds of PIs. A few larger trades.
GeordieChris,
"I'm sure more and more institutions will soon be getting in on the act"
Despite the company being portrayed as growing strongely for past 3 years:
There's no evidence of significant buying by institutionS in 2021, 2022, 2023. Where's the TR1s?
No evidence of significant holdings > 3% by institutionS.
Institutions take a punt all the time.
GeordieChris,
"I can't think of any other company who in January already has the full year revenue pretty much sewn up already as well as a significant inroad into 2025."
They do it every year. Because of the lead time to setup projects, they know which are planned over the following 12 months ++
The one's coming live currently would have been contracted 12-18months ago. Hence why I say there's a lack strong revenue growth.
This from a year ago, Jan 2023 - same 95% contracted for fy2023 plus some visibility into 2024. Same presentation format as last year.
"Over 95% of 2023 revenue guidance contracted and visibility into 2024. "
"The growing orderbook from new and existing Big Pharma and biotech clients provides excellent forward visibility with over 95% of forecasted revenue for 2023 contracted, and further revenue visibility into 2024. "
https://polaris.brighterir.com/public/hvivo/news/rns/story/w9j9mdx
TheSoundMan,
"They have a contracted Option to take a whole new floor at Canary Wharf when needed, and also an admission that they could expand into another country if they want to (so it's obviously been discussed)."
Any Landlord who has space available will willingly rent it out to you. Pointless having empty floors, producing no income.
The banks have been deserting Canary Wharf. The landlords need to get new tenants in, hence the offer.
In terms of expanding into another country. If there's demand what's stopping another company from setting up in say India/China. The Indians and Chinese could do it swiftly if the demand is there.
As examples, Serum Institute rapidly expanded capacity in India during covid to cope with worldwide demand. Indian/Chinese companies were quick to produce their own covid vaccines.
Why can't other companies enter the Challenge Trials space?